Thematics Asset Management Has $7.86 Million Stake in Boston Scientific Corporation $BSX

Key Points

• Thematics Asset Management reduced its holdings in Boston Scientific Corporation by 27.7%, now owning 77,896 shares valued at approximately $7.86 million post-sale.
• Boston Scientific reported better-than-expected earnings for the last quarter, achieving $0.75 EPS against an estimate of $0.72, contributing to a 22.8% year-over-year revenue increase.
• Several institutional investors have significantly increased their stakes in Boston Scientific, with GAMMA Investing LLC boosting its holdings by over 11,720% in the first quarter, now owning over 2.57 million shares.

Thematics Asset Management decreased its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 27.7% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 77,896 shares of the medical equipment provider's stock after selling 29,908 shares during the period. Thematics Asset Management's holdings in Boston Scientific were worth $7,858,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Boston Scientific by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after purchasing an additional 1,697,945 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in Boston Scientific by 2.5% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 22,312,967 shares of the medical equipment provider's stock worth $1,992,994,000 after buying an additional 554,388 shares in the last quarter. Invesco Ltd. lifted its position in Boston Scientific by 5.3% in the 1st quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider's stock worth $1,677,124,000 after buying an additional 834,274 shares in the last quarter. Northern Trust Corp lifted its position in Boston Scientific by 18.0% in the 4th quarter. Northern Trust Corp now owns 14,595,627 shares of the medical equipment provider's stock worth $1,303,681,000 after buying an additional 2,221,790 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Boston Scientific by 10.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock worth $1,426,779,000 after buying an additional 1,383,524 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Performance

BSX traded up $1.31 during trading on Tuesday, hitting $106.42. The stock had a trading volume of 5,613,286 shares, compared to its average volume of 6,216,135. The firm has a market cap of $157.69 billion, a PE ratio of 63.35, a P/E/G ratio of 2.53 and a beta of 0.66. Boston Scientific Corporation has a 12 month low of $79.03 and a 12 month high of $108.94. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The company has a 50 day simple moving average of $104.27 and a 200-day simple moving average of $102.15.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

BSX has been the subject of a number of research analyst reports. Royal Bank Of Canada reiterated an "outperform" rating on shares of Boston Scientific in a research report on Thursday, July 24th. Leerink Partners initiated coverage on shares of Boston Scientific in a research report on Monday, June 16th. They issued an "outperform" rating and a $118.00 target price for the company. Erste Group Bank upgraded shares of Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. Robert W. Baird increased their target price on shares of Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Finally, Truist Financial increased their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Boston Scientific presently has a consensus rating of "Buy" and a consensus price target of $117.50.

Insider Transactions at Boston Scientific

In related news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director owned 2,081 shares in the company, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Michael F. Mahoney sold 164,443 shares of Boston Scientific stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the completion of the transaction, the chief executive officer owned 1,476,882 shares in the company, valued at $153,137,894.58. This trade represents a 10.02% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 345,029 shares of company stock worth $35,976,603. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.